Abstract 183P
Background
In cancer, inflammation frequently coexists with hypoxia within the tumor microenvironment (TME), often creating an immunosuppressive environment. This hostile milieu is further exacerbated by acidosis, which collectively further hinders effective anti-tumor immune responses. Carbonic anhydrase IX (CAIX) is a well-established hypoxia marker that plays a key role in the pH regulation and adaptation of tumor cells to hypoxia resulting in tumor progression. The CAIX activity contributes to the formation of an acidic environment, which can suppress the function of cytotoxic T cells and other immune cells. While primarily induced by HIF1α under hypoxic conditions, CAIX expression can also be triggered in an inflammatory milieu by IL6 or the COX-2/PGE2 pathway. The goal of this study is to determine the role of CAIX in the regulation of inflammatory and anti-tumor immune responses.
Methods
CAIX+ and CAIX-silenced HT1080 cells were cultured in the presence of a conditioned (inflammatory) medium obtained from MUF spheroids (MUF-CM) under normoxic or hypoxic conditions. RNA samples were analyzed by Clariom, followed by unsupervised clustering. Gene Set Expression Analysis (GSEA) was used to analyze the gene expression. The relation between CAIX level and gene sets identified by GSEA was also analyzed in TCGA SARComa samples and pancreatic cancer (PC).
Results
We found that MUF-CM can upregulate CAIX expression in fibrosarcoma and PC cells even under normoxia. Our analysis revealed that suppression of CAIX leads to upregulation of hallmarks of IFN-α, IFN-γ, and inflammatory response. In silico analysis of TCGA SARC samples confirmed the relationship between lower CAIX expression and higher expression of IFN-α, IFN-γ and inflammation response gene sets, which predicted better overall survival. Moreover, the immune gene sets associated with immune activation and expression of HLA-antigens negatively correlated with CAIX.
Conclusions
Understanding the complex interplay between hypoxia, CAIX, and inflammation is crucial for developing effective cancer treatments. Given the central role of CAIX in this intricate relationship, targeting the function of this enzyme may represent a new opportunity to create a favorable milieu for anti-tumor immune response in the TME.
Legal entity responsible for the study
The authors.
Funding
The Slovak Research and Development Agency 20-0480.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
98P - Immuno-related cardiac toxicity: a prospective study applying multiparametric cardiac MRI
Presenter: Agnese Losurdo
Session: Poster Display session
Resources:
Abstract
99P - Real-world management of ir-colitis, a Danish 10-year cohort study
Presenter: Soeren Petersen
Session: Poster Display session
Resources:
Abstract
101P - Comparison on the effectiveness of multiple single and double immunotherapy treatments on advanced angiosarcoma patients: Meta analysis & systematic review
Presenter: Enzo Marson
Session: Poster Display session
Resources:
Abstract
102P - A real-world study of the efficacy of second-line treatment of unresectable hepatocellular carcinoma after progression on first-line lenvatinib combined with PD-1 inhibitor
Presenter: Saifeng Li
Session: Poster Display session
Resources:
Abstract
103P - Tislelizumab combined with chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: A multicenter, prospective, single-arm, real-world study
Presenter: zhihua wen
Session: Poster Display session
Resources:
Abstract
104P - The efficacy and safety of a novel PD-1/CTLA-4 bispecific antibody cadonilimab (AK104) as second- or later-line therapy for metastatic non-small cell lung cancer
Presenter: Hualin Chen
Session: Poster Display session
Resources:
Abstract
105P - A retrospective study using machine learning to analyze the effects of VEGFR-TKIs and PD-1 inhibitors as third-line or later treatment in patients with MSS mCRC
Presenter: Shumei Han
Session: Poster Display session
Resources:
Abstract
106P - Immunotherapy after progression to double immunotherapy: Pembrolizumab and Lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition
Presenter: Dimitrios Ziogas
Session: Poster Display session
Resources:
Abstract
107P - Efficacy and safety of first-line TKI plus ICI therapy in metastatic non-clear cell renal cell carcinoma: A real-world multiple-centre study
Presenter: Yulu Peng
Session: Poster Display session
Resources:
Abstract
108P - Transarterial chemoembolization (TACE) combined with atezolizumab and bevacizumab versus TACE alone in patients with Barcelona Clinic liver cancer stage B unresectable hepatocellular carcinoma: A retrospective, propensity score-matched analysis
Presenter: Hongjie Cai
Session: Poster Display session
Resources:
Abstract